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Abstract
Background: This study was designed to evaluate if erythropoietin (EPO) is effective in the
treatment of cancer related anemia, and if its effect remains unchanged when data are analyzed
according to various clinical and methodological characteristics of the studies. We also wanted to
demonstrate that cumulative meta-analysis (CMA) can be used to resolve uncertainty regarding
clinical questions.
Methods: Systematic Review (SR) of the published literature on the role of EPO in cancer-related
anemia. A cumulative meta-analysis (CMA) using a conservative approach was performed to
determine the point in time when uncertainty about the effect of EPO on transfusion-related
outcomes could be considered resolved. Participants: Patients included in randomized studies that
compared EPO versus no therapy or placebo. Main outcome measures: Number of patients
requiring transfusions.
Results: Nineteen trials were included. The pooled results indicated a significant effect of EPO in
reducing the number of patients requiring transfusions [odds ratio (OR) = 0.41; 95%CI: 0.33 to 0.5;
p < 0.00001;relative risk (RR) = 0.61; 95% CI: 0.54 to 0.68]. The results remain unchanged after the
sensitivity analyses were performed according to the various clinical and methodological
characteristics of the studies. The heterogeneity was less pronounced when OR was used instead
of RR as the measure of the summary point estimate. Analysis according to OR was not
heterogeneous, but the pooled RR was highly heterogeneous. A stepwise metaregression analysis
did point to the possibility that treatment effect could have been exaggerated by inadequacy in
allocation concealment and that larger treatment effects are seen at hb level > 11.5 g/dl. We
identified 1995 as the point in time when a statistically significant effect of EPO was demonstrated
and after which we considered that uncertainty about EPO efficacy was resolved.
Conclusion: EPO is effective in the treatment of anemia in cancer patients. This could have already
been known in 1995 if a CMA had been performed at that time.
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Background
A synthetic form of EPO, human recombinant EPO, has
been successfully used to treat anemia in patients with
chronic renal failure and HIV [1]. Some randomized trials
(RCT) assessed the role of EPO in anemia related the can-
cer [2,3]. However, many of these trials were underpow-
ered and failed to identify clinically meaningful benefits
of EPO treatment. As a result, there has been persistent un-
certainty about the efficacy of EPO as a treatment for can-
cer-related anemia, despite the introduction of EPO in a
clinical practice almost a decade ago. Systematic reviews
(SR) are the best way to offer synthesis of evidence and are
of special utility in settings where many small trials fail to
achieve a significant result [4].
A recent comprehensive SR [5,6] addressed the role of
EPO in treatment-related anemia in cancer patients. This
SR included non-randomized studies and performed a
meta-analysis (MA) of 12 RCTs showing a significant ef-
fect of EPO in reducing the need to transfuse patients who
are receiving chemotherapy. Although comprehensive,
some issues were not addressed in this previous SR/MA: a
formal quantitative synthesis (meta-analysis) was not per-
formed according to different clinical aspects and to main
methodological quality dimensions empirically linked to
bias [7].
In contrast to this previous report [5,6], in this SR we eval-
uated only data from randomized studies. We also inves-
tigated a broad range of clinical issues, including EPO use
according to the level of hemoglobin (hb), platinum-
based chemotherapy and tumor type. Finally, to investi-
gate the stability of our conclusions, a broad methodolog-
ical appraisal of the quality of the trials was performed,
specifically examining those dimensions that have been
empirically linked to bias [7].
We also performed a conservative cumulative meta-analy-
sis (CMA) [8] to determine the earliest point in time when
the use of EPO versus placebo reached a such statistical
significance after which the uncertainty [9] about the ef-
fect of EPO in cancer-related anemia could have been con-
sidered resolved.
Methods
A previous SR served as a basis for location of the articles
of interest [5]. We also performed a search of MEDLINE,
LILACS and CANCERLIT databases, last update in July of
2001, using the optimal search strategy for RCT for use in
MEDLINE [10] and LILACS [11] with the additional terms
related to this review – (epoetin OR Erythropoietin) and
(cancer OR neoplasm), in all fields.
We included only RCTs that compared EPO versus no
therapy or placebo in cancer related anemia. We excluded
studies related to transplant setting and myelodysplastic
syndrome, since the physiopathology of these diseases is
different, more linked to pancytopenia than to anemia
[1]. We also excluded trials that used EPO with the prima-
ry objective to magnify hb to improve the efficacy of radi-
otherapy.
Four trials described more than one comparison of differ-
ent doses of EPO with only one control group [12–15].
We approached these multi-arm studies in two different
ways: in the first, each EPO arm was compared to the con-
trol arm. In the second we combined all active arms in
one, by adding all EPO treated patients, and analyzed it
against the control. Both combinations achieved virtually
the same result and data are presented using the second
method.
Data were abstracted on patient characteristics, type of tu-
mor, treatment details and the major methodological
quality dimensions [4,7] (see Additional file 1). The end
point studied was the number of patients requiring trans-
fusions. Results in a conventional meta-analysis were
pooled using the Peto's Odds Ratio (OR) and relative risk
(RR), both in a fixed effect model [16]. We also extracted
data on adverse effects of the use of EPO.
Heterogeneity among trials was assessed using chi-square
test (chi). The possibility of publication bias was assessed
using the funnel plot method [17]. To assess the reasons
for any heterogeneity found, we performed a meta-regres-
sion [4]. Sensitivity and subgroup analyses according to
the main methodological quality dimensions [7] and a
number of clinical criteria were also performed (see fig 2
and 3). The results were calculated with corresponding
95% confidence interval (95%CI). When the results from
pooled data were significant, we calculated the number of
patients need to treat (NNT) [18] in order to prevent one
transfusion. However, the readers are advised to exercise
due caution because NNT and NNH (number of patients
to harm) are more influenced by the baseline risk in a con-
trol group than the odds ratio.
The qualitative conclusion of the authors was assessed us-
ing the method described by Gilberts and Colditz [19,20]
and adapted to a six point scale, where 1 = control group
highly preferred, 2 = control preferred to EPO treatment,
3 = about equal, EPO a disappointment, 4 = about equal,
EPO a success, 5 = EPO preferred to control and 6 = EPO
highly preferred.
Finally, we performed a cumulative meta-analysis (CMA)
[8] using a conservative approach, setting the  error at
1%, with a two tailored "p" in a random effects model
[21]. The CMA allowed us to determine the point when
the results achieved a level of statistical significance afterBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/23
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which we should expect no changes in the effect by per-
forming new trials, and after which placebo controlled tri-
als should not have been performed. In other words: CMA
allowed us to determine the threshold point after which
uncertainty about this question should have been consid-
ered resolved [9].
Results
Thirty-seven randomized articles addressing the use of
EPO in cancer related anemia were located and retrieved
for full text appraisal. Twenty one papers fit our inclusion
criteria. Two articles describing two small trials [22,23]
with a total of 79 patients were excluded from our analysis
because they did not provide information regarding our
end point of interest.
Nineteen articles [2,3,12–15,24–36] describing 21 trials
(see Additional file 1) fit our inclusion criteria. One paper
[3] described three different trials, two of which [24,26]
were reported later, in separate papers. We included data
from these latest papers only. Therefore, we included 19
trials from 19 articles with 1896 patients in cancer related
anemia. Fourteen trials with a total of 1511 patients de-
scribed the use of EPO in patients with hb level < 11.5 g/
dl and five trials with 369 patients related to hb level >=
11.5 g/dl. Of the latter ones, one trial [14] included pa-
tients with hb ranging from 10.6 to 12.0 g/dl. The analysis
did not change when we excluded this trial in the sensitiv-
ity analysis.
The possibility of publication bias was considered unlike-
ly according to the visual inspection of the funnel plot
Figure 1
Meta-analysis of EPO use in cancer patients n – number of events; N – number of patients; OR – odds ratio; CI – confi-
dence interval.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/23
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[17]. The results of the critical appraisal according to the
most important methodological quality dimensions of
each article are shown in (see Additional file 1). No single
trial met all methodological quality criteria. All trials
scored five or six on the six point Gilbert [19] and Colditz
[20] scales, denoting strong qualitative support in favor of
EPO ((see Additional file 1)).
The meta-analysis of the 19 trials (Fig 1 and 3) showed a
significant beneficial effect of EPO in diminishing the
number of patients requiring transfusion [OR = 0.41;
95%CI: 0.33 to 0.5 ; p < 0.00001], without statistical het-
erogeneity [chi = 23.46; df = 18; p > 0.1]. When we used
relative risk (fig 3) as a summary point estimate in the
meta-analysis, the results remained significant [RR = 0.61;
Figure 2
Sensitivity analysis using OR. Jadad – value according to Jadad's scale [39]; Adequate random – adequate method of rand-
omization described; Ad all conc – adequate method of allocation concealment used; Double blind trials – double blind trials;
Ad desc blind – adequate description of methods of blindness; Plan sample size – planning of the sample size; ITT – intention to
treat; Malig – malignancies; CDDP – cisplatin; Disease related anaemia – anaemia due to the effects of the cancer; Trea related
anaemia – anaemia due to effects of the treatment (chemotherapy and/or radiotherapy) Hb – hemoglobin level; G/dl – grams/
deciliter. N – number, * Carboplatin usedBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/23
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95% CI: 0.54 to 0.68; p < 0.00001], but now with signifi-
cant statistical heterogeneity: [chi = 37.56; df = 18; p =
0.0044]. However, when the study by Porter et al [29] was
removed from the analysis, heterogeneity disappeared
from the analysis, and the analysis according to OR or RR
did not differ. This is likely because in this small study in-
cluding 10 patients in each group, event rate was so high
with all but one patient receiving transfusion.
To further explain heterogeneity, we also performed a me-
taregression [4]. The variables related to the design and
clinical features which possible could affect the treatment
effect of EPO were entered in the equation (see Additional
file 1) We found no statistically significant association be-
tween any of the variables with the treatment effect of
EPO when all data were simultaneously entered in a mul-
tiregression equation(data not shown). However, when a
stepwise regression model was used, two variables
emerged of the potential significance which could explain
Figure 3
Analysis and sensitivity analysis using RR. (For legends, see fig 2)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/23
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most the heterogeneity of our results: (in)adequacy of al-
location concealment (p = 0.026) and Hb cut-off value of
11.5 g/dl (p = 0.046). The between study variation (tau2
estimate) was 0.0372 for the model containing no varia-
bles (i.e. the simple meta-analysis); this was reduced to al-
most zero in the final model. In addition, most likely
explanation of heterogeneity seen in our study is related
to a small sample size of the individual trials resulting in
random fluctuation of the effect between the studies.
When we divided the trials according to the hb level, using
11.5 g/dl as a cut-off point, the results remained essential-
ly unchanged (i.e. highly significant in favor of EPO) (fig
2 and 3).
Thus, it appears that the effect of EPO is a rather robust de-
spite heterogeneity noted in the meta-analysis
Sensitivity and subgroup analyses according to clinical
and methodological quality dimensions (Fig 2 and 3)
showed consistency in the results, favoring the use of
EPO. Statistical heterogeneity was noted for some of these
comparisons (see fig 2 and 3). It was related to the magni-
tude of the treatment effect and not to its significance,
since in all trials the point estimate of the effect favored
EPO. A stepwise metaregression analysis did point to the
possibility that treatment effect could have been exagger-
ated by inadequacy in allocation concealment and that
larger treatment effects are seen at hb level < 11.5 g/dl. The
heterogeneity was more common when we used RR than
when we used OR.
The overall result by pooling all trials indicates that for
each 5 cancer patients (95% CI: 4 to 7) using EPO, one pa-
tient will avoid transfusion. This result is maintained
when we separately analyzed the trials that included pa-
tients with hb level < 11.5 g/dl (NNT = 5; 95% CI: 4 to 8)
and Hb > 11.5 g/dl (NNT = 5; 95% CI: 3 to 9). These NNT
should be analyzed carefully, since they were calculated
from a pool of data that in some analysis were not homo-
geneous.
We also performed a CMA, (fig 4) using a conservative ap-
proach (i.e. setting  error at 1%). Our CMA demonstrat-
ed that by 1995 a high level of significance [OR = 0.52;
99%CI: 0.28 to 0.97; p = 0.0068]; [RR = 0.69; 99%CI: 0.53
to 0.90; p = 0.0003] about the benefit of EPO on reducing
the use of blood transfusions had been achieved. Beyond
this point, all new trials only improved the precision,
without adding any additional useful information. We es-
timated that 1240 patients, representing 65% of the total
number of cancer patients who participated in EPO stud-
ies, were enrolled in 13 placebo-controlled randomized
studies that were reported after 1995.
The previous SR[5]concluded that it was impossible to
reasonably distinguish between adverse events related to
EPO and concurrent treatments. We also tried to extract
data on adverse events, but were unable to make a reason-
able approach due to the poor reporting. Therefore, we de-
cided not to tabulate data on adverse events and perform
quantitative pooling.
Discussion
According to our overall analysis, administration of EPO
is related to an average 59% reduction in odds of requir-
ing a transfusion. A previous SR [5,6] pooled 12 trials that
used subcutaneous EPO (all also included in our analysis)
in a Bayesian MA reached results similar [OR = 0.38;
95%CI: 0.28 to 0.51] to ours. We could also demonstrate
consistency of the results when analyzed according to OR,
RR, various quality dimensions and many different clini-
cal settings (fig 2 and 3).
Due to these EPO effects, patients with cancer are expected
to have direct benefits through fewer transfusions and
lower exposure to anemia effects. Furthermore, all pa-
tients will benefit indirectly through conservation of the
blood supply.
The use of RR as summary statistics is less robust than
OR[4] and in this case resulted in greater heterogeneity
than the analysis based on OR (see fig 2 and 3). The esti-
mate the effects of EPO using RR indicated a smaller effect
than OR but both results were significant (p < 0.0001 in
both analysis). However, when events are common, the
OR may overestimate the effect of treatment[4]. Due to
these characteristics of the analysis, we choose to show
both (OR and RR) as a summary statistics. Nevertheless,
we should mention (see the RESULTS) that the most of
heterogeneity could be explained by high transfusion
rates in the trial by Porter et al. and inadequacy of alloca-
tion concealment in EPO trials. Similarly, it appears that
the larger treatment effects are seen when EPO is given in
the patients with hb > 11.5 g/dl.
Because it was not possible to extract data on quality of
life (QOL), this issue was not addressed here. However, a
recent systematic review by Bottomley et al [37] indicated
that solid evidence about the effect of EPO on this end
point is lacking. We should also mention that the high
cost of EPO has deterred its widespread acceptance [5]
and more studies using economic analysis should be done
to address the issue if the use of EPO is cost-effective.
A previous SR[5,6] found no increased incidence of ad-
verse events of EPO when compared with controls. We
also did not find any side effect of EPO consistently re-
ported among trials.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/23
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Figure 4
Cumulative meta-analysis of EPO trials. N – numberBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/23
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Our main goal here is to stress that the basic ethical re-
quirement to randomize patients in clinical trials is that
physicians and patients must not have preferences for any
of the therapies considered i.e. they should be in the state
of uncertainty or equipoise [9]. If uncertainty does not ex-
ist, it is felt to be unethical to ask patients to participate in
RCTs [9].
To assess if uncertainty regarding a clinical question exists,
researchers should evaluate the totality of pre-existing
knowledge: if we already knew that one treatment is supe-
rior to another, nothing new could be learned and we
would unnecessarily expose our patients to already
known inferior treatment by performing a new trial. We
showed here that if a SR/CMA had been used to formally
address the uncertainty regarding the effect of EPO in can-
cer patients, this uncertainty could have been conserva-
tively considered resolved (Fig 4) since 1995. Our
findings suggest that 65% of the cancer patients included
in this SR participated in placebo controlled clinical trials
that were reported after EPO was shown to be superior to
placebo. Had a CMA been performed prospectively, it is
possible that clinical trialists may have decided against in-
itiating 13 clinical trials. We should note that we analyzed
trials according to date of their report. It is conceivable
that some trials were initiated before 1995, but were re-
ported after 1995. However, this only means that the un-
certainty about the role of EPO could have been solved
even earlier (if these patients were available for CMA or a
large RCT). For example, if all 656 patients included in
randomized studies up to 1995 had participated in only
one, large, randomized study, the uncertainty about EPO
could have been solved earlier. An alternative approach to
large studies in solving uncertainty is to use CMA to mon-
itor accumulation of treatment effects in clinical trials
[38]. The technique of CMA is a powerful scientific instru-
ment to assess the significance of accumulated knowledge
[8,38]. In more than 100 CMA performed, there has never
been a single case where the point estimate switched to in-
dicate the opposite effect, once the difference between
treatments reached statistical significance [8].
Conclusion
EPO is highly effective for cancer-related anemia. This ef-
fect could have been detected in 1995 if CMA had been
performed at that time. The techniques of CMA should be
used more frequently in the future to preserve "the uncer-
tainty principle"[9] and protect patients who consent to
be randomized in clinical trials.
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